港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

陕西麦科奥特医药科技股份有限公司（临时代码）

成交量：- -

成交额：- -

市值：- -

市盈率：- -

高：- -

开：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：- -

香港流通股本：- -

量比：- -

换手率：- -

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

市销率: - -

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

12.4亿元！云顶新耀引进麦科奥特靶向CaSR/OGP受体激动剂多肽

云顶新耀(01952)附属与麦科奥特订立协议以于大中华区及其他亚洲市场商业化MT1013

新股消息 | 麦科奥特拟港股IPO 中国证监会要求说明历次增资及股权转让价格、定价依据及公允性

麦科奥特IPO：在研管线获批临床融资估值不增反降单一产品依赖明显市场竞争日益加剧

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/91218"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"91218","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91218\",,,,,undefined,":{"symbol":"91218","market":"HK","secType":"STK","nameCN":"陕西麦科奥特医药科技股份有限公司（临时代码）","latestPrice":0,"timestamp":1770883200000,"preClose":0,"halted":9,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":0,"latestTime":"02-12 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770946200000},"marketStatusCode":0,"adr":0,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1770859800000,1770868800000],[1770872400000,1770883200000]],"volumeRatio":0,"lotSize":100,"spreadScale":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91218\",,,,,undefined,":{"symbol":"91218","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/91218\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"91218\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"91218\",market:\"HK\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"91218\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609533412","title":"12.4亿元！云顶新耀引进麦科奥特靶向CaSR/OGP受体激动剂多肽","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533412","media":"药研界面","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609533412?lang=zh_cn&edition=fundamental","pubTime":"2026-02-05 13:56","pubTimestamp":1770270961,"startTime":"0","endTime":"0","summary":"根据协议，麦科奥特将获得人民币2亿元首付款，以及最高不超过人民币10.4亿元的潜在监管及商业里程碑款项，合计最高可达人民币12.4亿元。随着全球慢性肾脏病患者规模持续扩大，SHPT 及其相关治疗需求亦不断增长。关于MT1013：ABOUT MT1013MT1013是由陕西麦科奥特医药科技股份有限公司自主研发设计的作用于钙敏感受体且发挥成骨生长肽作用的全球首款针对继发性甲旁亢合并肾性骨病的开创性双功能多肽治疗药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205152238a47f0e2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205152238a47f0e2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["91218","BK1583","01952","BK1574","BK1161"],"gpt_icon":0},{"id":"2609144183","title":"云顶新耀(01952)附属与麦科奥特订立协议 以于大中华区及其他亚洲市场商业化MT1013","url":"https://stock-news.laohu8.com/highlight/detail?id=2609144183","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609144183?lang=zh_cn&edition=fundamental","pubTime":"2026-02-05 07:29","pubTimestamp":1770247770,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀 发布公告，于2026年2月4日，本公司的间接全资附属公司云顶新耀医药科技有限公司与陕西麦科奥特医药科技股份有限公司订立协议，据此麦科奥特已不可撤销授予该附属公司于中国及亚太区的MT1013的独家商业化授权，MT1013为全球首创的双靶点受体激动剂多肽，可同时靶向钙敏感受体及成骨生长肽受体，开发主要用于治疗继发性甲状旁腺功能亢进症，其中国III期临床研究正在进行中及相关临床开发费用将由麦科奥特承担。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","01952","91218","BK1161","BK1574"],"gpt_icon":0},{"id":"2585597148","title":"新股消息 | 麦科奥特拟港股IPO 中国证监会要求说明历次增资及股权转让价格、定价依据及公允性","url":"https://stock-news.laohu8.com/highlight/detail?id=2585597148","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585597148?lang=zh_cn&edition=fundamental","pubTime":"2025-11-21 20:30","pubTimestamp":1763728254,"startTime":"0","endTime":"0","summary":"证监会要求麦科奥特补充说明历次增资及股权转让价格、定价依据及公允性，是否实缴出资，是否存在未履行出资义务、抽逃出资、出资方式存在瑕疵的情形；就公司设立及历次股权变动是否合法合规进行核查，并出具结论性意见。据港交所9月29日披露，麦科奥特向港交所提交上市申请书，建银国际、招商证券国际为其联席保荐人。补充说明本次拟参与“全流通”股东所持股份是否存在被质押、冻结或其他权利瑕疵的情形。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372311.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91218"],"gpt_icon":0},{"id":"2577896557","title":"麦科奥特IPO：在研管线获批临床融资估值不增反降 单一产品依赖明显市场竞争日益加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2577896557","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577896557?lang=zh_cn&edition=fundamental","pubTime":"2025-10-24 10:37","pubTimestamp":1761273420,"startTime":"0","endTime":"0","summary":"　　近日，陕西麦科奥特医药科技股份有限公司向港交所主板提交上市申请，建银国际和招商证券国际为其联席保荐人。招股书显示，麦科奥特成立于2007年，致力于开发新一代双特异性/多特异性多肽药物，专注于代谢性疾病，尤其是肾脏相关疾病，以及心脑血管疾病。然而，在创始人光鲜履历及资本热捧的背后，公司实际上仍存在诸多隐忧，包括单一产品依赖明显，核心产品赛道竞争日益加剧，资本信心或不足D轮融资估值下降等。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-10-24/doc-infuyerr6182520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91218"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/91218\",params:#limit:6,delay:false,,,undefined,":[]}}